# September 29, 2026 — scheduled research retry [Home](../README.md) · [Latest](../LATEST.md) · [Calendar](../MILESTONES.md) Research checked through September 29, 2026, using seven-day overlap from last successful topic checks (September 5–6 onward), with priority to September 27–29. Source dates are distinct from posting, announcement, actual study dates and verification dates. 23 deduplicated sourced entries, 1 new labeled informal claim and 5 unchanged rumor follow-ups. All 28 topics received focused checks; all remain partial and full successful-check timestamps are preserved. A source gap is not a no-news conclusion. ## Findings - **2026-09-29 — HRS-1596 adds a planned once-weekly oral GLP-1/GIP program.** Sponsor development announcement and primary trial registry. [Notes](../topics/03_glp1.md#programs-and-next-milestones). - **2026-09-29 — Tirzepatide versus higher-dose semaglutide comparison depends on estimand.** Sponsor-reported conference indirect comparison. [Notes](../topics/03_glp1.md#programs-and-next-milestones). - **2026-09-29 — Orforglipron comparison extends to oral semaglutide 25 mg.** Sponsor-reported conference indirect comparison. [Notes](../topics/03_glp1.md#programs-and-next-milestones). - **2026-09-29 — Claims-data analysis compares semaglutide escalation with tirzepatide switching.** Sponsor-reported retrospective observational conference analysis. [Notes](../topics/07_cardiovascular.md#programs-and-next-milestones). - **2026-09-28 — Shorter pancreatic radiotherapy better preserves reported quality of life; survival advantage unproven.** Randomized phase 2 conference abstract and investigator-society report. [Notes](../topics/14_cancer_vaccines.md#programs-and-next-milestones). - **2026-09-28 — BHV-1530 opens a checkpoint-inhibitor combination cohort.** Sponsor trial-development announcement. [Notes](../topics/14_cancer_vaccines.md#programs-and-next-milestones). - **2026-09-28 — Prula-cel reports one-year lupus remission signals, with infections in half the safety cohort.** Sponsor phase 1 uncontrolled human results. [Notes](../topics/15_autoimmune.md#programs-and-next-milestones). - **2026-09-28 — Small radiosurgical-capsulotomy cohort reports sustained depression improvement.** Conference investigator report; prospective observational cohort. [Notes](../topics/10_ssri_antidepressants.md#programs-and-next-milestones). - **2026-09-28 — DAYBREAK meets vision noninferiority endpoints; 54% reach six-month Zenkuda intervals.** Sponsor phase 3 randomized topline. [Notes](../topics/18_hearing_vision.md#programs-and-next-milestones). - **2026-09-28 — Orthodontic telemonitoring study finds fewer recorded complications, with important selection bias.** peer-reviewed prospective comparative cohort. [Notes](../topics/25_dental.md#programs-and-next-milestones). - **2026-09-25 — New polygenic embryo-selection study will measure early pregnancy success.** Trial-registry announcement. [Notes](../topics/28_genetic_screening.md#programs-and-next-milestones). - **2026-09-25 — Three-year denosumab sequencing extension reports no clear between-group BMD advantage.** Peer-reviewed extension of open-label randomized trial; abstract reviewed. [Notes](../topics/11_joint_preservation.md#programs-and-next-milestones). - **2026-09-25 — TRONTIER 1 and 2 close recruitment; completion estimates move to February 2028.** Trial-registry update, no results. [Notes](../topics/08_alzheimers.md#programs-and-next-milestones). - **2026-09-23 — Singapore adds a Wegovy indication for noncirrhotic MASH.** Sponsor announcement of regulatory approval. [Notes](../topics/13_liver.md#programs-and-next-milestones). - **2026-09-23 — SUPREME-01 first participant dosed; recruitment continues.** sponsor development announcement; registry cross-check. [Notes](../topics/06_localized_fat.md#programs-and-next-milestones). - **2026-09-22 — IM-AGE registers a small study of less-invasive skin-aging measurements.** trial-registry registration. [Notes](../topics/20_skin_aging.md#programs-and-next-milestones). - **2026-09-17 — Engineered-phage STEPS-CF trial receives conditional UK authorization.** Sponsor-reported trial authorization; recovered overlap finding. [Notes](../topics/27_infectious_disease.md#programs-and-next-milestones). - **2026-09-14 — Hydrocolloid dressing speeds healing in a small experimental-wound trial.** peer-reviewed randomized within-person study. [Notes](../topics/21_scars.md#programs-and-next-milestones). - **2026-09-09 — BV100 adds a pivotal resistant-pneumonia program to the watch.** Historical baseline. Recovered baseline: sponsor development update and registries. [Notes](../topics/27_infectious_disease.md#programs-and-next-milestones). - **2026-09-04 — Completed everolimus aging study awaits results.** Historical baseline. Baseline addition from trial registry. [Notes](../topics/05_longevity.md#programs-and-next-milestones). - **2026-09 — Otarmeni reaches a U.S. treatment center outside clinical trials.** Historical baseline. Treating-center access announcement; recovered baseline. [Notes](../topics/18_hearing_vision.md#programs-and-next-milestones). - **2026-08-26 — Baseline addition: daraxonrasib approval includes randomized survival benefit in pancreatic cancer.** Historical baseline. Recovered FDA approval; historical baseline, not new September news. [Notes](../topics/14_cancer_vaccines.md#programs-and-next-milestones). - **2026-08-01 — Clascoterone rosacea pilot adds early indication-specific evidence.** Historical baseline. peer-reviewed single-arm phase 2 pilot; recovered baseline. [Notes](../topics/24_acne_rosacea.md#programs-and-next-milestones). ## Correction and access context Onswik approval was September 23, announced September 24. Current state receives a dated correction under the original event key; older logs are preserved. Awiqli’s earlier approval/launch and plan-dependent Medicare coverage are context, not new approvals or a recommendation to switch insulin. ## Coverage and remaining gaps ### Whole-body MRI **Status: focused, partial.** September 5–29 overlap discovery; refreshed HERCULES original API, screened recent human-outcome publications and podcast leads. No new controlled screening-outcome result was established in reviewed sources. **Gaps:** HERCULES remains an April 2025 registry snapshot (recruiting, 100,000 planned; January 2034/2037 estimates), not fresh enrollment confirmation. Full AJR review and repeat-screening cohort census remain incomplete. **Informal sources:** September 28 mindbodygreen Andrew Lacy episode title/show-note search surfaced a 200,000-scan claim, not a controlled benefit study. Full episode failed to render and audio was not reviewed; no new efficacy claim promoted. https://podcasts.apple.com/ie/podcast/what-200k-full-body-scans-reveal-about-how-we-age-andrew/id1246494475?i=1000791846530 **Sources checked:** [Source 1](https://clinicaltrials.gov/study/NCT06212479); [Source 2](https://pmc.ncbi.nlm.nih.gov/articles/PMC13504611/). ### Galleri and organ-specific cancer screening **Status: focused, partial.** Rechecked FDA September 23 summary and sponsor release index; searched screening developments through September 29 and colorectal-test discovery. **Gaps:** No final FDA decision verified. Full panel recording/transcript and new SDC2 September 17 paper remain unappraised; organ-specific registry census incomplete. **Informal sources:** Recent approval speculation repeats the already recorded advisory vote. No original new dated approval rumor selected; newspaper/investor commentary is not an FDA decision. **Sources checked:** [Source 1](https://www.fda.gov/media/195032/download); [Source 2](https://grail.gcs-web.com/news-events/news-releases); [Source 3](https://link.springer.com/article/10.1186/s12876-026-05338-8). ### GLP-1 and related metabolic therapies **Status: focused, partial.** September 5–29 overlap with September 27–29 focus: EASD sponsor announcements, new oral program discovery, HRS-1596 and enicepatide registries, weekly insulin correction/access. **Gaps:** Not a complete worldwide incretin/diabetes registry or safety census. EASD SPOTLIGHT original abstract not retrieved; Reddit numbers not treated as established. Enicepatide registry still lists week-36 co-primary endpoints versus week-48 sponsor topline. **Informal sources:** Read September 28 eloralintide discussion and September 29 SPOTLIGHT Reddit post; claims may mix studies/populations. No original-data leak selected. https://www.reddit.com/r/Eloralintide/comments/1wsjbhw/easd_abstract_about_eloralintide_and_tirzepatide/ ; https://www.reddit.com/r/NovoNordisk_Stock/comments/1wtdtla/novo_presents_china_realworld_study_of_160000/ . Full podcast recordings not reviewed. **Sources checked:** [Source 1](https://www.prnewswire.com/news-releases/hengrui-pharma-and-novo-enter-exclusive-license-agreement-for-once-weekly-oral-glp-1gip-dual-receptor-agonist-hrs-1596-302892378.html); [Source 2](https://investor.lilly.com/news-releases/news-release-details/lillys-zepbound-tirzepatide-10-mg-and-15-mg-was-associated-more); [Source 3](https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-orforglipron-172-mg-showed-greater-weight-loss); [Source 4](https://www.prnewswire.com/news-releases/novos-ozempic-semaglutide-2-mg-associated-with-lower-risk-of-major-adverse-cardiovascular-events-death-heart-attack-and-stroke-in-adults-with-type-2-diabetes-compared-to-switching-to-mounjaro-tirzepatide-in-real-world--302892049.html); [Source 5](https://clinicaltrials.gov/study/NCT07841860); [Source 6](https://clinicaltrials.gov/study/NCT06628362); [Source 7](https://www.lilly.com/hcp/congresses/easd-2026); [Source 8](https://onswik.lilly.com/); [Source 9](https://www.prnewswire.co.uk/news-releases/novos-ozempic-semaglutide-2-mg-associated-with-lower-risk-of-major-adverse-cardiovascular-events-death-heart-attack-and-stroke-in-adults-with-type-2-diabetes-compared-to-switching-to-mounjaro-tirzepatide-in-real-world--302892062.html); [Source 10](https://www.streetinsider.com/PRNewswire/Novos%2BOzempic%C2%AE%2B%28semaglutide%29%2B2%2Bmg%2Bassociated%2Bwith%2Blower%2Brisk%2Bof%2Bmajor%2Badverse%2Bcardiovascular%2Bevents%2B%28death%2C%2Bheart%2Battack%2C%2Band%2Bstroke%29%2Bin%2Badults%2Bwith%2Btype%2B2%2Bdiabetes%2Bcompared%2Bto%2Bswitching%2Bto%2BMounjaro/27116510.html); [Source 11](https://www.prnewswire.com/apac/news-releases/novo-receives-singapore-approval-for-wegovy-as-first-treatment-for-mash-with-liver-fibrosis-302886853.html). ### Muscle building and preservation **Status: focused, partial.** Rechecked BELIEVE/EloraTZP EASD schedule and Veru development releases; no newly verified result beyond September27 withdrawal abstract. **Gaps:** September30 BELIEVE presentation is still future; full slide deck not appraised. Original Cantor audio and all global muscle-drug registries unreviewed. **Informal sources:** Enobosarm conference direction remains unconfirmed; no formal Phase 3 enrollment or design confirmation found in reviewed sponsor releases. Reddit search mostly repeats prior mass/function results. **Sources checked:** [Source 1](https://www.lilly.com/hcp/congresses/easd-2026); [Source 2](https://ir.verupharma.com/news-events/press-releases). ### Longevity and healthspan drug trials **Status: focused, partial.** TAME/rapamycin/senolytic discovery; fresh everolimus, PEARL and MAVRIC registries; original PEARL publication checked against a dubious secondary story. **Gaps:** TAME actual funded launch remains unverified. MAVRIC still not yet recruiting despite September28 estimated start. RESTOR and worldwide geroscience census incomplete; no full podcast sweep. **Informal sources:** A September19 blog asserts a September17 Nature Aging 24-month PEARL paper, but no such original was found; the verified primary report is April4,2025, 48 weeks in Aging. Excluded unsupported claim from findings, retained as source-quality gap. https://usalongevitytoday.com/rapamycins-first-randomized-human-aging-trial-posts-its-data/ . Current forum material largely recycled preclinical/mechanistic claims. **Sources checked:** [Source 1](https://www.afar.org/tame-trial); [Source 2](https://clinicaltrials.gov/study/NCT05835999); [Source 3](https://clinicaltrials.gov/study/NCT07520110); [Source 4](https://clinicaltrials.gov/study/NCT04488601); [Source 5](https://www.aging-us.com/article/206235/text). ### Localized fat removal **Status: focused, partial.** Selective September 5–29 overlap, emphasizing September 27–29; prior September 27 findings deduplicated. Refreshed SUPREME-01, AYP-101 and tesamorelin original API records; searched RZL-012, cellulite and new human-stage programs; recovered September 23 first-dose release. **Gaps:** No new Phase 3 efficacy or independent SUPREME-02 enrollment milestone verified. September 30 VAT talk not yet occurred; full human abstract unresolved. Cellulite comparative census incomplete. **Informal sources:** Reddit/talk and candidate searches mainly returned Dercum reposts and tesamorelin self-experimentation/sourcing, excluded; no new attributed formal-development rumor selected. **Sources checked:** [Source 1](https://www.caliwaybiopharma.com/en/news-detail/-CBL-514-SUPREME-01-FPI-ObesityWeek-2026-ENG/); [Source 2](https://www.caliwaybiopharma.com/en/news/); [Source 3](https://clinicaltrials.gov/study/NCT07140939); [Source 4](https://clinicaltrials.gov/study/NCT06256445); [Source 5](https://clinicaltrials.gov/study/NCT03375788). ### Broad cardiovascular prevention, lipid therapies and screening **Status: focused, partial.** Rechecked lipid/prevention news, pelacarsen repeat-news deduplication and new COMPETE SWITCH CV observational report. **Gaps:** Not all VERVE/olpasiran/lepodisiran or screening registries refreshed. Original COMPETE table, HR orientation, event counts and prevention-setting split not retrieved. **Informal sources:** September28 CRISPR Reddit headline recycles earlier experimental lipid-lowering context; no independently verified new readout from that post. https://www.reddit.com/r/Cholesterol/comments/1wspp8m/crispr_phase_1_trial_big_reductions/ . Existing obicetrapib Alzheimer-prevention hypothesis not reevaluated beyond cross-topic coverage; no new benefit inferred. **Sources checked:** [Source 1](https://www.prnewswire.com/news-releases/novos-ozempic-semaglutide-2-mg-associated-with-lower-risk-of-major-adverse-cardiovascular-events-death-heart-attack-and-stroke-in-adults-with-type-2-diabetes-compared-to-switching-to-mounjaro-tirzepatide-in-real-world--302892049.html); [Source 2](https://www.streetinsider.com/PRNewswire/Novos%2BOzempic%C2%AE%2B%28semaglutide%29%2B2%2Bmg%2Bassociated%2Bwith%2Blower%2Brisk%2Bof%2Bmajor%2Badverse%2Bcardiovascular%2Bevents%2B%28death%2C%2Bheart%2Battack%2C%2Band%2Bstroke%29%2Bin%2Badults%2Bwith%2Btype%2B2%2Bdiabetes%2Bcompared%2Bto%2Bswitching%2Bto%2BMounjaro/27116510.html); [Source 3](https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd); [Source 4](https://www.prnewswire.co.uk/news-releases/novos-ozempic-semaglutide-2-mg-associated-with-lower-risk-of-major-adverse-cardiovascular-events-death-heart-attack-and-stroke-in-adults-with-type-2-diabetes-compared-to-switching-to-mounjaro-tirzepatide-in-real-world--302892062.html). ### Alzheimer's screening and therapies **Status: focused, partial.** September 5–29 overlap, prioritizing Sep27–29: symptomatic and prevention discovery; fresh TRONTIER1/2 registry APIs; huperzine controlled-release phase2/3 registry; no duplication of XanaMIA/RADIANT. **Gaps:** All antibody labels, diagnostic-clearance/recall databases and prevention registries not comprehensively refreshed. Huperzine program is an older August record, not new September launch. ALZ101/PrevenTRON exact registry matching remains unresolved. **Informal sources:** Indexed informal/new-program searches found no new source-grounded clinical-benefit signal; full podcasts and paid transcripts not reviewed. Existing obicetrapib hypothesis not reclassified. **Sources checked:** [Source 1](https://clinicaltrials.gov/study/NCT07169578); [Source 2](https://clinicaltrials.gov/study/NCT07170150); [Source 3](https://clinicaltrials.gov/study/NCT07066826). ### Psilocybin and related investigational therapies **Status: focused, partial.** September 5–29 overlap, new sponsor/registry/readout discovery and recent Compass discussions. September28 COMP360 newsletter recounts July data and was deduplicated. **Gaps:** FDA September14 hearing full transcript and MDMA resubmission acceptance remain unappraised. All current study registries and conference posters not refreshed. **Informal sources:** Sep28/29 Reddit thread speculates October NDA/approval timing and cites LinkedIn hiring; no inside source, hiring verification or new official date. Not selected as a separate meaningful alert; approval certainty is unsupported. Original recordings not reviewed. **Sources checked:** [Source 1](https://www.ghres.com/our-work/clinical-trials); [Source 2](https://ir.definiumtx.com/sec-filings/all-sec-filings/content/0001104659-26-107275/tm2625365d1_ex99-2.htm); [Source 3](https://www.reddit.com/r/shroomstocks/comments/1wse09j/rshroomstocks_weekly_discussion_thread_september/). ### Mental-health treatments, SSRIs and newer antidepressants **Status: focused, partial.** September 5–29 overlap, prioritized new depression/OCD results and ASTRO primary investigator release; fasedienol/DT120 prior events deduplicated. **Gaps:** Full ASTRO abstract and controlled replication absent. All SSRI, bipolar, PTSD and addiction registries not refreshed; no comprehensive safety-label census. **Informal sources:** Targeted Reddit SSRI/trial searches mainly general criticism and patient discussion, not a new attributable human-program signal. No comprehensive podcast review. **Sources checked:** [Source 1](https://www.astro.org/news-and-publications/news-and-media-center/news-releases/2026/incisionless-radiosurgery-shows-promise-for-severe%2C-treatment-resistant-depression); [Source 2](https://www.psychiatrist.com/pcc/atypical-depression-obstructive-sleep-apnea-screening/). ### Cancer treatment, vaccines and recurrence prevention **Status: focused, partial.** September 5–29 discovery plus older approval-baseline repair; appraised ASTRO pancreatic abstract, Biohaven combination enrollment/registry and FDA daraxonrasib approval. **Gaps:** Not a complete cancer/line-of-therapy census. SOFT registry identifier and full toxicity appendix unresolved. The September 27–28 setidegrasib presentation window has elapsed; actual delivery and full results were not verified. Cancer-vaccine and radiopharmaceutical registries not comprehensively refreshed. **Informal sources:** Searched cancer trial interview/podcast and Reddit leads. September28 hospital story repeated August daraxonrasib approval; no new attributable rumor selected. Full conference interview audio not reviewed. **Sources checked:** [Source 1](https://www.astro.org/news-and-publications/news-and-media-center/news-releases/2026/short-course-radiation-therapy-better-preserves-physical-function-before-pancreatic-cancer-surgery); [Source 2](https://amportal.astro.org/sessions/lba-01-22916/a-randomized-phase-ii-clinical-trial-of-stereotactic-body-radiation-therapy-or-conventionally-114057); [Source 3](https://ir.biohaven.com/news-releases/news-release-details/biohavens-clinical-data-bhv-1530-novel-fgfr3-directed-adc); [Source 4](https://clinicaltrials.gov/study/NCT06874335); [Source 5](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma). ### Autoimmune disease modification and immune-reset therapies **Status: focused, partial.** September 5–29 overlap, prula-cel sponsor release/full clinical slides and original phase1 registry; general autoimmune/CAR-T failure discovery, prior IMVT/ORKA/OCTOPUS dedup. **Gaps:** All ACR abstracts and other autoimmune registries not comprehensively refreshed. Full investor webcast audio not reviewed; no head-to-head CAR-T safety inference. **Informal sources:** Sep28 lupus Reddit discussions repeat Adicet results. Cross-trial claims of safer donor cells are not proven. Mount Sinai IBD planning source not freshly reopened; status cannot be advanced. **Sources checked:** [Source 1](https://investor.adicetbio.com/news-releases/news-release-details/adicet-bio-announces-positive-safety-and-efficacy-data-prula-cel/); [Source 2](https://investor.adicetbio.com/static-files/89b0896a-002e-4a20-8af0-69f286ec4c94); [Source 3](https://clinicaltrials.gov/study/NCT06375993). ### Sleep therapies and sleep disorders **Status: focused, partial.** September 5–29 overlap, orexin/insomnia/digital and circadian publication discovery; already-saved oveporexton/alixorexton publications deduplicated. **Gaps:** New Sep28 BMC digital-sleep network meta-analysis found, but full paper failed to open and quantitative quality appraisal remains pending. Current drug scheduling/launch, apnea and restless-legs registries not comprehensively refreshed. **Informal sources:** Sep24/27 narcolepsy threads contain trial anecdotes and claims of cheap Japanese access; no verified U.S. launch/coverage or new efficacy signal. Reposts of May/June sleep abstracts were not treated as September results. **Sources checked:** [Source 1](https://www.nejm.org/doi/abs/10.1056/NEJMoa2601598); [Source 2](https://pubmed.ncbi.nlm.nih.gov/42636845/); [Source 3](https://link.springer.com/article/10.1186/s12916-026-05129-8); [Source 4](https://academic.oup.com/sleep/article/49/9/zsag154/8699387). ### Liver disease, fibrosis and noninvasive assessment **Status: focused, partial.** Singapore regulatory announcement, CHMP agenda follow-up, NATiV3/MASH discovery and September announcements. **Gaps:** Independent HSA letter and CHMP September MASH outcome not recovered. Global fibrosis and noninvasive-test review incomplete. AASLD page showed conflicting 2025/2026 dates and was not treated as new study evidence. **Informal sources:** CHMP Reddit inference remains unresolved; old lanifibranor investor timing/odds discussion not independent evidence. https://www.reddit.com/r/biotech_stocks/comments/1uz61q4/inventiva_pharma_update/ . Original conference/podcast recordings not reviewed. **Sources checked:** [Source 1](https://www.prnewswire.com/apac/news-releases/novo-receives-singapore-approval-for-wegovy-as-first-treatment-for-mash-with-liver-fibrosis-302886853.html); [Source 2](https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-14-17-september-2026_en.pdf); [Source 3](https://www.globenewswire.com/de/news-release/2026/09/08/3358086/0/en/inventiva-to-present-multiple-abstracts-at-paris-mash-2026.html). ### Kidney preservation and earlier CKD detection **Status: focused, partial.** Sefaxersen/IgAN and broader renal-outcome/discovery queries through September29; deduplicated September23 topline. Identified FT819 grant lead for autoimmune cross-check and retrospective SPOTLIGHT lead. **Gaps:** No complete CKD/detection registry census. SPOTLIGHT original abstract and FT819 grant details not independently appraised in this assignment. New abstracts and full safety tables need follow-up. **Informal sources:** Kidney Reddit and clinical-discussion queries mainly patient accounts; a Healios AKI/ARDS talk claim was found but original Japanese schedule not appraised, so no new clinical result asserted. https://www.reddit.com/r/ATHX/comments/1wsphlk/hardy_to_present_in_japanese_this_weekend_on_the/ . No full podcast review. **Sources checked:** [Source 1](https://www.roche.com/media/releases/med-cor-2026-09-23b); [Source 2](https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916767); [Source 3](https://www.nephjc.com/front-page-next-generation); [Source 4](https://investor.adicetbio.com/news-releases/news-release-details/adicet-bio-announces-positive-safety-and-efficacy-data-prula-cel/); [Source 5](https://investor.adicetbio.com/static-files/89b0896a-002e-4a20-8af0-69f286ec4c94); [Source 6](https://clinicaltrials.gov/study/NCT06375993). ### Bone health, joint preservation and cartilage repair **Status: focused, partial.** Denosumab sequencing extension, osteoporosis/cartilage discovery, Biosplice/Entera updates; refreshed parent and cartilage pilot registries. **Gaps:** Denosumab extension full paper/sample size/AE counts unavailable. Lorecivivint EMA submission unverified, EB613 actual phase 3 initiation unverified. No full cartilage/fracture census. NCT06400862 remains a stale May2024 registry despite September29 third-party refresh. **Informal sources:** Osteoporosis Reddit queries mostly exercise anecdotes and old FORTIFY completion expectations; no newly attributable drug-development rumor selected. Full conference audio not reviewed. **Sources checked:** [Source 1](https://doi.org/10.1016/j.jfma.2026.09.029); [Source 2](https://clinicaltrials.gov/study/NCT03868033); [Source 3](https://clinicaltrials.gov/study/NCT06400862); [Source 4](https://www.biosplice.com/news/default.aspx); [Source 5](https://investors.enterabio.com/). ### Non-opioid acute and chronic pain therapies **Status: focused, partial.** September 5–29 overlap, non-opioid human-trial discovery and Sep28–29 Pain Therapeutics Summit agenda; NOHARM Sep28 institutional repost deduplicated. **Gaps:** Tonix PAINWeek poster link failed to open; underlying pooled NNT/NNH results not appraised. VX993/Tonmya/suzetrigine full registries and clinical safety not comprehensively refreshed. Conference schedules are not result evidence. **Informal sources:** No new attributable development rumor selected from indexed pain/patient discussion; original conference talks and audio not reviewed. **Sources checked:** [Source 1](https://www.tonixpharma.com/scientific-presentations/); [Source 2](https://paintherapeuticsummit.com/component/sppagebuilder/page/53); [Source 3](https://rethinkingclinicaltrials.org/news/category/news/). ### Hearing and vision preservation/restoration **Status: focused, partial.** September 5–29 overlap, DAYBREAK release/registry, Otarmeni access, AC102 original registry and retinal gene/atrophy conference discovery. **Gaps:** DAYBREAK full slides/CI/margin and safety tables not appraised; current PRIMA/other ophthalmology labels and broader hearing registries incomplete. Gildeuretinol Retina Society narrative requires original slides before new result attribution. **Informal sources:** AC102 original secondhand-email claim remains unconfirmed; registry still January 16 snapshot with elapsed estimates, not proof of completed phase2 or 2027 tinnitus/phase 3 launch. New indexed searches did not resolve original email. **Sources checked:** [Source 1](https://www.prnewswire.com/news-releases/zenkuda-and-tabirafusp-ted-meet-primary-endpoints-in-pivotal-daybreak-trial-in-wamd-with-zenkuda-demonstrating-a-potential-new-standard-of-care-profile-with-strong-immediacy-and-sustained-clinical-effect-with-majority-of-patients-302891194.html); [Source 2](https://clinicaltrials.gov/study/NCT06556368); [Source 3](https://childrenswi.org/medical-professionals/latest-news/gene-therapy-for-genetic-hearing-loss); [Source 4](https://clinicaltrials.gov/study/NCT05776459); [Source 5](https://ir.kodiak.com/news-releases/news-release-details/kodiak-sciences-announces-recent-business-highlights-and-first-1); [Source 6](https://www.fda.gov/vaccines-blood-biologics/otarmeni). ### Hair loss and hair restoration **Status: focused, partial.** Selective September 5–29 overlap, emphasizing September 27–29; prior September 27 findings deduplicated. Refreshed PP405 AWAKEN, ABS-201 HEADLINE and BioCopper registries; Q32 news and EADV release timing; revisited existing rumors. **Gaps:** AWAKEN remains not yet recruiting in September 18 record despite estimated September start. Bempikibart off-drug presentation remains September 30. Full Kintor/Veradermics program and webcast review incomplete. **Informal sources:** Existing BQ-002 original post and BioQ site, plus Cosmo guidance rechecked; timing rumors unchanged. Recent tressless search mostly personal regimens/compounding anecdotes; no new development claim promoted. **Sources checked:** [Source 1](https://clinicaltrials.gov/study/NCT07819435); [Source 2](https://clinicaltrials.gov/study/NCT07317544); [Source 3](https://clinicaltrials.gov/study/NCT07839494); [Source 4](https://ir.q32bio.com/news-and-events/news-releases); [Source 5](https://eadv.org/wp-content/uploads/2026/03/EADV-Congress-Media-Embargo-Policy-2026.pdf). ### Skin aging, laxity and regeneration **Status: focused, partial.** Selective September 5–29 overlap, emphasizing September 27–29; prior September 27 findings deduplicated. Discovered IM-AGE methods study and Dermial supplement trial; refreshed KB304 record and searched visible rejuvenation/energy procedures. **Gaps:** IM-AGE registry chronology and completion fields conflict. Dermial NCT07790237 is recruiting, no results, estimated March 31 2028 completion; full supplement evidence appraisal deferred. KB304 remains stale in registry and no new Phase 2 first dosing established. **Informal sources:** September 16 Biohacking Beauty interview with Mamina Turegano show description reviewed via indexed original listing; no precise new trial result/forecast established. Complete podcast audio not reviewed. **Sources checked:** [Source 1](https://www.isrctn.com/ISRCTN10674073); [Source 2](https://clinicaltrials.gov/study/NCT07790237); [Source 3](https://clinicaltrials.gov/study/NCT06724900). ### Facial volume restoration and contour **Status: focused, partial.** Selective September 5–29 overlap, emphasizing September 27–29; prior September 27 findings deduplicated. Refreshed macrofat retention registry and searched randomized filler/fat-transfer/biostimulator comparisons. **Gaps:** NCT07805889 unchanged; no results and retrospective-registration limitations retained. August 30 HA-collagen perioral RCT and July 25 nasolabial filler paper located, but full methods/safety not newly appraised. Broad EuropePMC endpoint returned 503. **Informal sources:** Targeted informal searches mainly returned personal aesthetic experiences and commercial roundups, not new trial-specific statements; no new rumor selected. **Sources checked:** [Source 1](https://clinicaltrials.gov/study/NCT07805889); [Source 2](https://onlinelibrary.wiley.com/doi/full/10.1111/jocd.71169); [Source 3](https://link.springer.com/article/10.1007/s13555-026-01847-2). ### Scar prevention, treatment and stretch marks **Status: focused, partial.** Selective September 5–29 overlap, emphasizing September 27–29; prior September 27 findings deduplicated. Appraised full September 14 hydrocolloid RCT; refreshed Geneva verteporfin, SCARFREE and siSPARC/IL4RA registries; searched Syntara and new scar/stretch-mark programs. **Gaps:** Verteporfin records still not yet recruiting despite elapsed estimates. siSPARC record unknown/stale; complete new siRNA paper appraisal remains open. SNT-9465 Q3 recruitment forecast not confirmed achieved. Broad EuropePMC discovery endpoint returned 503, limiting census. **Informal sources:** Targeted Reddit/scar and Syntara searches did not recover a new attributable formal-program rumor; self-experimentation not promoted. Full investor recordings unreviewed. **Sources checked:** [Source 1](https://pmc.ncbi.nlm.nih.gov/articles/PMC13574720/); [Source 2](https://clinicaltrials.gov/study/NCT06944249); [Source 3](https://clinicaltrials.gov/study/NCT07488988); [Source 4](https://clinicaltrials.gov/study/NCT06138964); [Source 5](https://syntaratx.com.au/wp-content/uploads/2025/11/Skin-scarring-program-to-progress-on-positive-Phase-1a-results.pdf). ### Pigmentation and uneven skin tone **Status: focused, partial.** Selective September 5–29 overlap, emphasizing September 27–29; prior September 27 findings deduplicated. Refreshed DelVito; checked EADV original schedule/embargo; searched melasma/PIH/vitiligo primary papers and deduplicated prior findings. **Gaps:** EADV abstracts become available September 30, not a completed readout now. No full reappraisal of all STOP-V safety tables, KT-939 filings or delayed pigment recurrence. Bulk EuropePMC discovery returned 503. **Informal sources:** Targeted melasma/clinical-trial Reddit and podcast searches found no new specific attributable development signal; full audio/transcript census not completed. **Sources checked:** [Source 1](https://clinicaltrials.gov/study/NCT07820098); [Source 2](https://investor.incyte.com/news-releases/news-release-details/incyte-data-european-academy-dermatology-and-venereology-eadv); [Source 3](https://eadv.org/wp-content/uploads/2026/03/EADV-Congress-Media-Embargo-Policy-2026.pdf). ### Acne and rosacea **Status: focused, partial.** Selective September 5–29 overlap, emphasizing September 27–29; prior September 27 findings deduplicated. Refreshed SP0268 and redness-study records; appraised older clascoterone rosacea abstract and related registry; read September 21 single-case RF report. **Gaps:** Clascoterone related registry remains stale and primary-endpoint interpretation needs full-paper reconciliation. SP0268 still recruiting without results. RF report is one off-label case, not meaningful comparative evidence. EuropePMC API 503 limited discovery. **Informal sources:** Recent informal rosacea/hair episode and targeted searches did not establish a new trial-specific rumor; case-report author discloses device consulting, and protocol is not validated. **Sources checked:** [Source 1](https://pubmed.ncbi.nlm.nih.gov/42555080/); [Source 2](https://clinicaltrials.gov/study/NCT06952517); [Source 3](https://clinicaltrials.gov/study/NCT06316297); [Source 4](https://clinicaltrials.gov/study/NCT07521462); [Source 5](https://pubmed.ncbi.nlm.nih.gov/42799195/). ### Dental alignment, regeneration and repair **Status: focused, partial.** Selective September 5–29 overlap, emphasizing September 27–29; prior September 27 findings deduplicated. Appraised full September 28 caregiver-selected telemonitoring cohort; refreshed direct-printed aligner registry and Toregem original news; searched enamel/repair, acceleration, retention and root/gum outcomes. **Gaps:** Toregem archive still ends in August; Phase IIa first dosing unverified. Direct-printed aligner trial remains not yet recruiting despite elapsed September estimates. Broader retention/acceleration studies and complete jRCT record not appraised. **Informal sources:** September25–26 tooth-regrowth posts repeat known TRG035 background and extrapolate to implants without new human results; no material rumor status change. Orthodontic podcast/transcript search remains selective. **Sources checked:** [Source 1](https://www.frontiersin.org/journals/dental-medicine/articles/10.3389/fdmed.2026.1959672/full); [Source 2](https://clinicaltrials.gov/study/NCT07496892); [Source 3](https://toregem.co.jp/en/news); [Source 4](https://www.mdpi.com/2304-6767/14/9/564). ### Allergy and airway disease **Status: focused, partial.** September 6–29 overlap, rademikibart COPD/VIASKIN filing and new airway trial discovery; cross-link STEPS-CF. **Gaps:** September COPD readout and Q3 VIASKIN filing not verified complete; neither window has elapsed on September29. Environmental/food-allergy, sinus and full ERS source/registry census incomplete. **Informal sources:** Reddit investor posts repeat September CNTB forecasts; DBV secondary conference transcript echoes filing plans. No original recording establishing a completed filing/result was appraised. **Sources checked:** [Source 1](https://www.globenewswire.com/news-release/2026/09/15/3361907/0/en/connect-biopharma-announces-positive-preliminary-topline-data-from-its-global-phase-2-study-of-rademikibart-as-an-add-on-treatment-for-acute-exacerbations-in-adult-and-adolescent-p.html); [Source 2](https://saspiphi.com/news.html); [Source 3](https://www.sec.gov/Archives/edgar/data/1613780/000162828026048453/dbvt-20260630.htm); [Source 4](https://www.isrctn.com/ISRCTN57413769). ### Infectious-disease prevention and treatment **Status: focused, partial.** September 6–29 overlap, primary SASPject conditional authorization and BV100 sponsor/registry reconciliation; antibiotic/phage/vaccine/antiviral human discovery. **Gaps:** STEPS-CF registry holding page blocks independent trial-detail confirmation. RIV-CARE record stale and sponsor/registry RIV-TARGET enrollment targets differ. Alpibectir phase2b/c and meningeal trial lead not fully registry-matched. Full ENCORE, Utebzi launch, prevention/vaccine safety registries remain gaps. **Informal sources:** Phage/antibiotic Reddit searches mostly preclinical studies, general commentary and AI summaries. No new attributable trial rumor selected; podcast transcript coverage incomplete. **Sources checked:** [Source 1](https://saspiphi.com/news.html); [Source 2](https://ir.bioversys.com/news/bioversys-reports-half-year-2026-results-bv100-pivotal-riv-target-trial-actively-recruiting-alpibectir-phase-2bc-underway/b1979958-6896-4f23-aed5-0fb65e3d4b76); [Source 3](https://clinicaltrials.gov/study/NCT07326540); [Source 4](https://clinicaltrials.gov/study/NCT07431307); [Source 5](https://www.idsociety.org/practice-guideline/personalized-bacteriophage-therapy/); [Source 6](https://www.isrctn.com/ISRCTN57413769); [Source 7](https://ir.bioversys.com/news/bioversys-granted-fast-track-designation-from-us-fda-for-bv100/e31677b7-80df-4899-a91f-a21e51eed27f). ### Genetic screening and risk prediction **Status: focused, partial.** September 6–29 discovery covering PRS, inherited screening, newborn sequencing, pharmacogenomics and reproductive testing. Verified Nucleus new registry and unchanged PATHS-T1D; reviewed commercial-model/social claim distinction. **Gaps:** Full Nucleus protocol/statistical plan and whitepaper were not appraised; no prospective offspring outcome verified. Newborn September28 JAMA item is a perspective, not a new outcome study. International prospective-utility and ancestry-calibration census incomplete. **Informal sources:** September27 Reddit Vitruvian claim is saved separately as unconfirmed interpretation. Primary company page describes modeled highest-to-lowest score spreads, not observed child outcomes; original social announcement was not located. **Sources checked:** [Source 1](https://clinicaltrials.gov/study/NCT07841769); [Source 2](https://clinicaltrials.gov/study/NCT07802496); [Source 3](https://jamanetwork.com/journals/jama/article-abstract/2854584); [Source 4](https://mynucleus.com/labs). ## Rumors and informal statements - **Informal claim — unconfirmed: Vitruvian can increase a child’s IQ by 14 points:** A September 27 r/singularity post reproduces an attributed Nucleus announcement claiming a 14-point benefit. The original social post was not located; this is a secondhand quotation, not a verified offspring outcome. [September 27 Reddit source (secondhand)](https://www.reddit.com/r/singularity/comments/1wrq633/introducing_vitruvian_a_genetic_optimization/); [Nucleus model update](https://mynucleus.com/labs). - **Enobosarm phase 3 plans — unconfirmed:** No actual Phase 3 start/design confirmation in reviewed Veru releases. Original Cantor audio still unreviewed. [Source](https://ir.verupharma.com/news-events/press-releases). - **Wegovy European MASH review — unconfirmed:** Agenda remains verified, September procedure outcome unresolved. Singapore approval does not resolve the EU procedure. [Source](https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-14-17-september-2026_en.pdf). - **AC102 phase 3 and tinnitus plans — unconfirmed:** Fresh original registry API remains January 16, active-not-recruiting, with February 28/July 31 estimated completion. No verified confirmation of reported 2027 phase 3/tinnitus plans; no repeat alert. [Source](https://clinicaltrials.gov/study/NCT05776459); [Source](https://www.reddit.com/r/tinnitusresearch/comments/1w1vebv/audiocure_ac102_update/). - **Clascoterone U.S. launch speculation — unconfirmed:** Cosmo guidance still forecasts Q1 2027 U.S. filing; no verified launch date. Community late 2027/2028 availability inference remains unconfirmed. [Source](https://www.cosmohealthconfidence.com/news/64300770-h1-2026); [Source](https://www.reddit.com/r/tressless/comments/1v6rr61/clascoterone_wont_be_available_until_q4_2027_at/). - **BQ002 human-trial timing — unconfirmed:** Original post and sponsor site rechecked; candidate existence is corroborated, candidate-specific human trial and 2027 start still unverified. [Source](https://www.reddit.com/r/greyhairreversal/comments/1t0k55l/bioq_is_developing_an_injectable_drug_bq002/); [Source](https://www.bioq.com/). ## Publication and interpretation Indirect and observational metabolic comparisons were not inserted into randomized-trial plots. The polygenic embryo-selection study measures early pregnancy outcomes, not lifetime offspring health or traits. CBL first-dose day is undisclosed; September 23 is its announcement date. September 30 presentations remain upcoming at this check. New historical findings retain baseline labels. Canonical notes were verified before export. Website publication is tracked separately; the public edition omits personal notes and identifying context. Source and rendered-page checks are not browser QA.